TScan Therapeutics Inc. (TCRX)
2.65
0.02 (0.76%)
At close: Jan 15, 2025, 11:50 AM
undefined% (undefined)
| Bid | 2.64 |
| Market Cap | 141.43M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.95 |
| PE Ratio (ttm) | -2.79 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.66 |
| Volume | 32,753 |
| Avg. Volume (20D) | 413,272 |
| Open | 2.70 |
| Previous Close | 2.63 |
| Day's Range | 2.63 - 2.71 |
| 52-Week Range | 2.60 - 9.69 |
| Beta | undefined |
About TCRX
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors....
Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2021
Employees 188
Stock Exchange NASDAQ
Ticker Symbol TCRX
Website https://www.tscan.com
Analyst Forecast
According to 5 analyst ratings, the average rating for TCRX stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 315.09% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
TScan Therapeutics Inc. is scheduled to release its earnings on Mar 5, 2025,
before market opens.
Analysts project revenue of $1.28M, reflecting a -82.25% YoY shrinking and earnings per share of -0.3, making a 42.86% increase YoY.
Analysts project revenue of $1.28M, reflecting a -82.25% YoY shrinking and earnings per share of -0.3, making a 42.86% increase YoY.
9 months ago ·
Source
-7.28%
TScan Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
